The present invention provides methods of inducing sedation in a subject by administering an effective amount of a compound or a mixture of compounds according to Formula I. Compounds of Formula I are a class of halogenated alcohol derivatives with a vapor pressure of less than 0.1 atmospheres (76 m
The present invention provides methods of inducing sedation in a subject by administering an effective amount of a compound or a mixture of compounds according to Formula I. Compounds of Formula I are a class of halogenated alcohol derivatives with a vapor pressure of less than 0.1 atmospheres (76 mmHg) at 25° C. The compounds of the present invention can be administered by any route sufficient to achieve a desired anesthetic, amnestic, analgesic, or sedative effect.
대표청구항▼
1. A method of inducing sedation in a subject, comprising administering to the subject via the respiratory system an effective amount of a compound or a mixture of compounds of Formula I: wherein:n is 0-4,R1 is H;R2, R3, R4, R5 and R6 independently are selected from H, X, CX3, CHX2, CH2X and C2X5; a
1. A method of inducing sedation in a subject, comprising administering to the subject via the respiratory system an effective amount of a compound or a mixture of compounds of Formula I: wherein:n is 0-4,R1 is H;R2, R3, R4, R5 and R6 independently are selected from H, X, CX3, CHX2, CH2X and C2X5; andwherein X is a fluorine, the administered compound having a vapor pressure of less than 0.1 atmospheres (76 mmHg) at 25° C., and the number of hydrogen atoms in Formula I do not exceed the number of carbon atoms, thereby inducing sedation in the subject. 2. The method of claim 1, wherein the administered compound has a vapor pressure selected from the group consisting of 0.095 atm, 0.09 atm, 0.085 atm, 0.08 atm, 0.075 atm, 0.07 atm, 0.065 atm, 0.06 atm, 0.055 atm, 0.05 atm, 0.045 atm, 0.04 atm, 0.035 atm, 0.03 atm, 0.025 atm, 0.02 atm, 0.015 atm, 0.01 atm, 0.0095 atm, 0.009 atm, 0.0085 atm, 0.008 atm, 0.0075 atm, 0.007 atm, 0.0065 atm, 0.006 atm, 0.0055 atm, 0.005 atm, and 0.0045 atm. 3. The method of claim 1, wherein the administered compound has a vapor pressure between about 0.005 and 0.1 atm. 4. The method of claim 3, wherein the administered compound has a vapor pressure about 0.01 atm. 5. The method of claim 3, wherein the administered compound has a vapor pressure of 0.01 atm. 6. The method of claim 3, wherein the administered compound has a vapor pressure of about 0.005 atm. 7. The method of claim 3, wherein the administered compound has a vapor pressure of 0.005 atm. 8. The method of claim 1, wherein the compound has a molar water solubility of less than about 1.1 mM and greater than about 0.016 mM. 9. The method of claim 1, wherein the compound potentiates GABAA receptors, but does not inhibit NMDA receptors. 10. The method of claim 1, wherein the subject is a mammal. 11. The method of claim 1, wherein the subject is a human. 12. A composition comprising a compound or a mixture of compounds used in the methods of claim 1, wherein the composition is formulated for inhalational or pulmonary delivery of the compound or mixture of compounds. 13. The method of claim 1, wherein the compound is selected from the group consisting of: a) 1-Butanol, 2,3,3,4,4,4-hexafluoro-2-(trifluoromethyl)-(CAS#111736-92-6);b) 2-Pentanol, 1,1,1,3,3,4,5,5,5-nonafluoro-, (R*,S*)-(9C1) (CAS#99390-96-2);c) 2-Pentanol, 1,1,1,3,3,4,4,5,5,5-decafluoro-2-(trifluoromethyl)-(CAS#67728-22-7);d) 2-Pentanol, 1,1,1,3,3,4,4,5,5,5-decafluoro-(CAS#377-53-7);e) 1-Pentanol, 2,2,3,4,4,5,5,5-octafluoro-(CAS#357-35-7);f) 1-Butanol, 2,3,4,4,4-pentafluoro-2-(trifluoromethyl)-(CAS#357-14-2);g) 1-Pentanol, 2,2,3,3,4,4,5,5,5-nonafluoro (CAS#355-28-2);h) 2-Butanol, 1,1,1,3,3,4,4,4-octafluoro (CAS#127256-73-9);i) 2-Propanol, 1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)-(CAS#2378-02-01);j) 1-Hexanol, 3,3,4,4,5,5,6,6,6-nonafluoro-(CAS#2043-47-2);k) 1-Hexanol, 2,2,3,3,4,4,5,5,6,6,6-undecafluoro-(CAS#423-46-1);l) 1-Hexanol, 2,2,3,4,4,5,5,6,6,6-decafluoro-(CAS#356-25-2);m) 1-Heptanol, 3,3,4,4,5,5,6,6,7,7,7-undecafluoro-(CAS#185689-57-0); andn) 1-Hexanol, 4,5,5,6,6,6-hexafluoro-4-(trifluoromethyl)-(CAS#239463-96-8). 14. A method of inducing sedation in a subject, comprising administering to the subject an effective amount of a compound or a mixture of compounds of Formula I: wherein:n is 0-4,R1 is H;R2, R3, R4, R5 and R6 independently are selected from H, X, CX3, CHX2, CH2X and C2X5; andwherein X is a fluorine, the administered compound having a vapor pressure of less than 0.1 atmospheres (76 mmHg) at 25° C., and the number of hydrogen atoms in Formula I do not exceed the number of carbon atoms, thereby inducing sedation in the subject. 15. The method of claim 14, wherein the administering comprises administering by any route sufficient to achieve a desired sedative effect. 16. The method of claim 14, wherein the compound is selected from the group consisting of: a) 1-Butanol, 2,3,3,4,4,4-hexafluoro-2-(trifluoromethyl)-(CAS#111736-92-6);b) 2-Pentanol, 1,1,1,3,3,4,5,5,5-nonafluoro-, (R*,S*)-(9C1) (CAS#99390-96-2);c) 2-Pentanol, 1,1,1,3,3,4,4,5,5,5-decafluoro-2-(trifluoromethyl)-(CAS#67728-22-7);d) 2-Pentanol, 1,1,1,3,3,4,4,5,5,5-decafluoro-(CAS#377-53-7);e) 1-Pentanol, 2,2,3,4,4,5,5,5-octafluoro-(CAS#357-35-7);f) 1-Butanol, 2,3,4,4,4-pentafluoro-2-(trifluoromethyl)-(CAS#357-14-2);g) 1-Pentanol, 2,2,3,3,4,4,5,5,5-nonafluoro (CAS#355-28-2);h) 2-Butanol, 1,1,1,3,3,4,4,4-octafluoro (CAS#127256-73-9);i) 2-Propanol, 1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)-(CAS#2378-02-01);j) 1-Hexanol, 3,3,4,4,5,5,6,6,6-nonafluoro-(CAS#2043-47-2);k) 1-Hexanol, 2,2,3,3,4,4,5,5,6,6,6-undecafluoro-(CAS#423-46-1);l) 1-Hexanol, 2,2,3,4,4,5,5,6,6,6-decafluoro-(CAS#356-25-2);m) 1-Heptanol, 3,3,4,4,5,5,6,6,7,7,7-undecafluoro-(CAS#185689-57-0); andn) 1-Hexanol, 4,5,5,6,6,6-hexafluoro-4-(trifluoromethyl)-(CAS#239463-96-8). 17. The method of claim 14, wherein the subject is a mammal. 18. The method of claim 14, wherein the subject is a human. 19. The method of claim 16, wherein the compound is 1-Butanol, 2,3,3,4,4,4-hexafluoro-2-(trifluoromethyl)- (CAS# 111736-92-6). 20. The method of claim 1, wherein the compound is 2-Pentanol, 1,1,1,3,3,4,5,5,5-nonafluoro-, (R*, S*)- (9C1) (CAS# 99390-96-2). 21. The method of claim 16, wherein the compound is 2-Pentanol, 1,1,1,3,3,4,4,5,5,5-decafluoro-2-(trifluoromethyl)- (CAS# 67728-22-7). 22. The method of claim 16, wherein the compound is 2-Pentanol, 1,1,1,3,3,4,4,5,5,5-decafluoro- (CAS# 377-53-7). 23. The method of claim 16, wherein the compound is 1-Pentanol, 2,2,3,4,4,5,5,5-octafluoro- (CAS# 357-35-7). 24. The method of claim 16, wherein the compound is 1-Butanol, 2,3,4,4,4-pentafluoro-2-(trifluoromethyl)- (CAS# 357-14-2). 25. The method of claim 16, wherein the compound is 1-Pentanol, 2,2,3,3,4,4,5,5,5-nonafluoro (CAS# 355-28-2). 26. The method of claim 16, wherein the compound is 2-Butanol, 1,1,1,3,3,4,4,4-octafluoro (CAS# 127256-73-9). 27. The method of claim 16, wherein the compound is 2-Propanol, 1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)- (CAS# 2378-02-01). 28. The method of claim 16, wherein the compound is 1-Hexanol, 3,3,4,4,5,5,6,6,6-nonafluoro- (CAS# 2043-47-2). 29. The method of claim 16, wherein the compound is 1-Hexanol, 2,2,3,3,4,4,5,5,6,6,6-undecafluoro- (CAS# 423-46-1). 30. The method of claim 16, wherein the compound is 1-Hexanol, 2,2,3,4,4,5,5,6,6,6-decafluoro- (CAS# 356-25-2). 31. The method of claim 16, wherein the compound is 1-Heptanol, 3,3,4,4,5,5,6,6,7,7,7-undecafluoro- (CAS# 185689-57-0). 32. The method of claim 16, wherein the compound is 1-Hexanol, 4,5,5,6,6,6-hexafluoro-4-(trifluoromethyl)- (CAS# 239463-96-8).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (8)
Squire Edward N. (Glen Mills PA), 4,5-Dichloro-2,2,4,5,-tetrafluoro-1,3-dioxolane.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.